10-04-2025 17:01 via medpagetoday.com

Benefits in Myasthenia Gravis Extend to 52 Weeks With Inebilizumab

(MedPage Today) -- SAN DIEGO--Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR) antibody-positive, data from the MINT...

Leaked HHS Budget Draft Deletes Federal Spending for SHIP Counseling Programs

Believers Say Microdosing Psychedelics Helps as Scientists Try to Measure the Claims

American Doc Told to 'Self-Deport'; FDA Ends Food Inspections; New Measles Outbreaks

Medical Journals Get Letters From DOJ

Hearing Loss May Play a Bigger Role in Dementia Than Previously Thought

Study Questions New Proposal to Redefine Obesity

For Pregnant Women With Mechanical Valves, LMWH Tied to Worse Outcomes

State Bans PBMs From Owning Pharmacies

Clinicians Worry About Loss of a Critical CDC Contraceptive Guideline

Leaked Budget Document Confirms Axed CDC Offices

MD Reacts to RFK Jr.'s Autism Comments; 'The Pitt' Memes; Nurse 'Would You Rather'?

Truly Novel RA Drug Passes Mid-Stage Test

NIH Centers Slashed, Consolidated in Leaked HHS Budget Document

What's at Stake if CDC's Infection Control Practices Committee Is Cut

Desktop versie

Benefits in Myasthenia Gravis Extend to 52 Weeks With Inebilizumab

Medical Industry news